Tracer library / [89Zr]DFO-F8

[89Zr]DFO-F8

Also written as [Zr-89]Zr-DFO-F8
Radionuclide
Zr-89 t½ 4704 min
Modality
PET
Production route
—
Stage
Reported once
Syntheses indexed
2
Breast cancerPreclinical only, no clinical indication yet

What it is

Compound class
DFO-conjugated F8 antibody targeting extra domain A of fibronectin (immuno-PET/theranostic construct)
Target / mechanism
Extra domain A of fibronectin (extracellular matrix protein overexpressed in TNBC stroma) PMID 41537706
Clinical application
—
Theranostic pair
—

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesis—SPE——p-SCN-Bn-DFO
Macrocyclics
41537706
2026 Clin Cancer Res
F8 was buffer exchanged into PBS (pH 8.5) prepared with chelex 100 resin via a 50 kDa MWCO Amicon spin filter, and incubated with p-SCN-Bn-DFO (Macrocyclics #B-705) in a 1:6 molar ratio at 37 °C and 300 rpm for 60 minutes.
————>99%DFO-B7-H3mab41207336
2026 Eur J Pharm Sci

Precursor

Common precursor
—
Suppliers seen in the literature
—
Cited suppliers in indexed syntheses
Macrocyclics
Typical final purification
—

Need this precursor?We can point you to suppliers for [89Zr]DFO-F8, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41537706. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41537706: 'p-SCN-Bn-DFO (Macrocyclics #B-705)'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Zr-89 is a positron emitter used only for PET imaging. Linked articles: PMID 41207336, 41537706.
Ask a question